Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations
Relief Therapeutics (SIX:RLF, OTCQB:RLFTF, OTCQB:RLFTY) announced plans to file Form 15F with the SEC on December 17, 2024, to terminate its U.S. securities registration and reporting obligations. The company will maintain its primary listing on the SIX Swiss Exchange, continue its Level 1 ADR program, and maintain its OTCQB quotation.
The filing will immediately suspend SEC reporting requirements, including Forms 20-F and 6-K, with full termination expected 90 days after submission. This decision follows the company's previous choice not to pursue a U.S.-regulated exchange listing after filing Form 20-F in 2021. The move aims to reduce compliance costs while maintaining strategic flexibility.
Relief Therapeutics (SIX:RLF, OTCQB:RLFTF, OTCQB:RLFTY) ha annunciato piani per presentare il Modulo 15F alla SEC il 17 dicembre 2024, per terminare la propria registrazione e gli obblighi di reporting sui titoli negli Stati Uniti. L'azienda manterrà la propria quotazione principale sul SIX Swiss Exchange, continuerà il suo programma ADR di Livello 1 e manterrà la sua quotazione OTCQB.
La presentazione sospenderà immediatamente i requisiti di reporting della SEC, inclusi i Moduli 20-F e 6-K, con termine completo previsto 90 giorni dopo la presentazione. Questa decisione segue la scelta precedente dell'azienda di non perseguire una quotazione su un mercato regolamentato negli Stati Uniti dopo aver presentato il Modulo 20-F nel 2021. L'iniziativa mira a ridurre i costi di conformità mantenendo flessibilità strategica.
Relief Therapeutics (SIX:RLF, OTCQB:RLFTF, OTCQB:RLFTY) anunció planes para presentar el Formulario 15F ante la SEC el 17 de diciembre de 2024, con el objetivo de terminar su registro de valores en EE.UU. y sus obligaciones de informe. La compañía mantendrá su cotización primaria en el SIX Swiss Exchange, continuará su programa ADR de Nivel 1 y mantendrá su cotización en OTCQB.
La presentación suspenderá inmediatamente los requisitos de informe de la SEC, incluidos los Formularios 20-F y 6-K, con una finalización completa esperada 90 días después de la presentación. Esta decisión sigue a la elección anterior de la empresa de no buscar una cotización en un intercambio regulado en EE.UU. tras presentar el Formulario 20-F en 2021. El movimiento tiene como objetivo reducir los costos de cumplimiento mientras se mantiene la flexibilidad estratégica.
Relief Therapeutics (SIX:RLF, OTCQB:RLFTF, OTCQB:RLFTY)는 2024년 12월 17일 SEC에 Form 15F를 제출하여 미국 증권 등록 및 보고 의무를 종료할 계획을 발표했습니다. 이 회사는 SIX Swiss Exchange에서의 주 거래를 유지하고, Level 1 ADR 프로그램을 계속하며, OTCQB 상장을 유지할 것입니다.
이번 제출로 SEC 보고 요구 사항, 즉 Form 20-F 및 6-K가 즉시 중단되며, 제출 후 90일 이내에 완전 종료될 것으로 예상됩니다. 이 결정은 회사가 2021년 Form 20-F를 제출한 후 미국 규제 거래소 상장을 추구하지 않기로 한 이전 선택에 따른 것입니다. 이 조치는 준수 비용을 줄이는 동시에 전략적 유연성을 유지하는 것을 목표로 합니다.
Relief Therapeutics (SIX:RLF, OTCQB:RLFTF, OTCQB:RLFTY) a annoncé ses plans de déposer le Formulaire 15F auprès de la SEC le 17 décembre 2024, pour mettre fin à son enregistrement de valeurs mobilières et à ses obligations de reporting aux États-Unis. La société conservera sa cotation principale sur le SIX Swiss Exchange, continuera son programme ADR de Niveau 1 et maintiendra sa cotation OTCQB.
Le dépôt suspendra immédiatement les exigences de reporting de la SEC, y compris les Formulaires 20-F et 6-K, avec une cessation complète attendue 90 jours après la soumission. Cette décision fait suite au choix précédent de l'entreprise de ne pas poursuivre une cotation sur un marché réglementé aux États-Unis après avoir déposé le Formulaire 20-F en 2021. Ce mouvement vise à réduire les coûts de conformité tout en maintenant une flexibilité stratégique.
Relief Therapeutics (SIX:RLF, OTCQB:RLFTF, OTCQB:RLFTY) gab bekannt, dass es plant, am 17. Dezember 2024 das Formular 15F bei der SEC einzureichen, um seine Registrierung von Wertpapieren und Berichtspflichten in den USA zu beenden. Das Unternehmen wird seine Hauptnotierung an der SIX Swiss Exchange beibehalten, sein Level 1 ADR-Programm fortsetzen und seine OTCQB-Notierung aufrechterhalten.
Die Einreichung wird die Berichtspflichten der SEC sofort aussetzen, einschließlich der Formulare 20-F und 6-K, wobei eine vollständige Beendigung 90 Tage nach der Einreichung erwartet wird. Diese Entscheidung folgt der vorherigen Wahl des Unternehmens, keine Notierung an einer regulierten Börse in den USA zu verfolgen, nachdem es 2021 das Formular 20-F eingereicht hatte. Der Schritt zielt darauf ab, die Compliance-Kosten zu senken und gleichzeitig strategische Flexibilität zu wahren.
- Reduction in compliance costs through termination of SEC reporting obligations
- Maintenance of existing SIX Swiss Exchange listing and OTCQB trading
- Reduced transparency for U.S. investors due to termination of SEC reporting
- Abandonment of plans for U.S.-regulated exchange listing
Company to Maintain SIX Swiss Exchange Listing, U.S. ADR Program, and U.S. OTCQB Quotation
GENEVA, SWITZERLAND / ACCESSWIRE / December 13, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that it intends to file a Form 15F with the United States Securities and Exchange Commission (SEC) on December 17, 2024. This filing seeks to terminate the registration of its ordinary shares under Section 12(g) of the Securities Exchange Act of 1934 (Exchange Act) and its reporting obligations under Section 15(d) of the Exchange Act.
This filing will not affect the Company's listing on the SIX Swiss Exchange, where its shares will continue to be traded. Relief will also continue to maintain its Level 1 American Depositary Receipt (ADR) program, with its shares and ADRs continuing to be quoted on the U.S. over-the-counter market (OTCQB).
Upon filing the Form 15F, Relief's reporting obligations with the SEC, including the filing of annual reports on Form 20-F and reports on Form 6-K, will immediately be suspended. Relief expects these obligations will be fully terminated 90 days following submission of the Form 15F. Relief remains current with its reporting requirements under the Exchange Act, and information regarding the Company, including financial reports and press releases, will continue to be available in English on its website at www.relieftherapeutics.com.
In 2021, Relief filed a Form 20-F registration statement with the SEC to support a potential listing of its securities on a U.S.-regulated stock exchange. As previously reported, the Company subsequently decided not to pursue this listing, and after further evaluation, has now concluded that maintaining its SEC registration is no longer beneficial. This decision will allow Relief to reduce its compliance costs and maintain flexibility in pursuing its strategic objectives. If in future the Company elects to conduct a transformative business transaction, it may reassess pursuit of a regulated exchange listing in the United States.
ABOUT RELIEF
Relief is a commercial-stage biopharmaceutical company committed to advancing treatment paradigms and delivering improvements in efficacy, safety, and convenience to benefit the lives of patients living with select specialty and rare diseases. Relief's portfolio offers a balanced mix of marketed, revenue-generating products, proprietary, globally patented TEHCLO™ and Physiomimic™ platform technologies and a targeted clinical development pipeline consisting of risk-mitigated assets focused in three core therapeutic areas: rare skin diseases, rare metabolic disorders, and rare respiratory diseases. In addition, Relief is commercializing several legacy products via licensing and distribution partners. Headquartered in Geneva, Relief is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, visit www.relieftherapeutics.com.
CONTACT :
RELIEF THERAPEUTICS Holding SA
Jeremy Meinen
Chief Financial Officer
contact@relieftherapeutics.com
DISCLAIMER
This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, including its ability to achieve its corporate, development and commercial goals, and other factors which could cause the actual results, financial condition, performance or achievements of Relief to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. A number of factors, including whether the Company's reporting obligations with the SEC will be fully terminated 90 days after its filing of the Form 15F, and those factors described in Relief's filings with the SIX Swiss Exchange and the SEC could adversely affect Relief. Copies of Relief's filings with the SEC are available on the SEC EDGAR database at www.sec.gov. Relief does not undertake any obligation to update the information contained herein, which speaks only as of this date.
SOURCE: Relief Therapeutics Holding SA
View the original press release on accesswire.com
FAQ
What is the impact of Relief Therapeutics (RLFTY) Form 15F filing on December 17, 2024?
Will Relief Therapeutics (RLFTY) continue trading on U.S. markets after Form 15F filing?
How long will it take for Relief Therapeutics' SEC reporting obligations to fully terminate?
Why is Relief Therapeutics (RLFTY) terminating its SEC reporting obligations in December 2024?
